398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) effectively treat patients with non-small cell lung cancer (NSCLC) with EGFR-sensitizing mutations; however, almost all will eventually relapse due to new mutations on or after osimertinib the 3rd generation TKI. The current standard of care is platinum doublet chemotherapy after progression on osimertinib, but with limited benefit. Amivantamab, an EGFR and MET bispecific humanized antibody, has shown clinical activity against tumors with primary activating EGFR mutations, EGFR resistance mutations, or MET pathway activation.